Immunotech Biopharm Ltd (HK:6978) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immunotech Biopharm Ltd has announced the transfer of its RMB300 million Convertible Bonds from Tasly (Hong Kong) Pharmaceutical Investment Limited to Tibet Jiaze Venture Capital Co., Ltd, pending several conditions. The transfer reflects strategic movements in the financial market and highlights the venture capital interest in biotech industries. Upon completion, the bonds’ terms will remain unchanged, maintaining the financial stability of the arrangement.
For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.